Literature DB >> 12796491

Transgenic mice expressing lipoprotein lipase in adipose tissue. Absence of the proximal 3'-untranslated region causes translational upregulation.

Lori L Hensley1, Gouri Ranganathan, Elke M Wagner, Brian D Wells, Joseph C Daniel, Diane Vu, Clay F Semenkovich, Rudolf Zechner, Philip A Kern.   

Abstract

Lipoprotein lipase (LPL) is a key enzyme in lipoprotein and adipocyte metabolism. Defects in LPL can lead to hypertriglyceridemia and the subsequent development of atherosclerosis. The mechanisms of regulation of this enzyme are complex and may occur at multiple levels of gene expression. Because the 3'-untranslated region (UTR) is involved in LPL translational regulation, transgenic mice were generated with adipose tissue expression of an LPL construct either with or without the proximal 3'-UTR and driven by the aP2 promoter. Both transgenic mouse colonies were viable and expressed the transgene, resulting in a 2-fold increase in LPL activity in white adipose tissue. Neither mouse colony exhibited any obvious phenotype in terms of body weight, plasma lipids, glucose, and non-esterified fatty acid levels. In the mice expressing hLPL with an intact 3'-UTR, hLPL mRNA expression approximately paralleled hLPL activity. However in the mice without the proximal 3'-UTR, hLPL mRNA was low in the setting of large amounts of hLPL protein and LPL activity. In previous studies, the 3'-UTR of LPL was critical for the inhibitory effects of constitutively expressed hormones, such as thyroid hormone and catecholamines. Therefore, these data suggest that the absence of the 3'-UTR results in a translationally unrepressed LPL, resulting in a moderate overexpression of adipose LPL activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796491     DOI: 10.1074/jbc.M304200200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Identification and characterization of a novel 5 bp deletion in a putative insulin response element in the lipoprotein lipase gene.

Authors:  Li-Xia Yang; Hamid Razzaghi; John E Hokanson; M Ilyas Kamboh
Journal:  Biochim Biophys Acta       Date:  2009-06-27

2.  Transgenic expression and genetic variation of Lmf1 affect LPL activity in mice and humans.

Authors:  Maryam Hosseini; Nicole Ehrhardt; Daphna Weissglas-Volkov; Ching-Mei Lai; Hui Z Mao; Jo-Ling Liao; Elina Nikkola; André Bensadoun; Marja-Riitta Taskinen; Mark H Doolittle; Päivi Pajukanta; Miklós Péterfy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-02-16       Impact factor: 8.311

3.  Defective thermoregulation, impaired lipid metabolism, but preserved adrenergic induction of gene expression in brown fat of mice lacking C/EBPbeta.

Authors:  M Carmen Carmona; Elayne Hondares; M Luisa Rodríguez de la Concepción; Víctor Rodríguez-Sureda; Julia Peinado-Onsurbe; Valeria Poli; Roser Iglesias; Francesc Villarroya; Marta Giralt
Journal:  Biochem J       Date:  2005-07-01       Impact factor: 3.857

4.  Adipose tissue-specific inhibition of hypoxia-inducible factor 1{alpha} induces obesity and glucose intolerance by impeding energy expenditure in mice.

Authors:  Xinmei Zhang; Karen S L Lam; Hongying Ye; Sookja K Chung; Mingyan Zhou; Yu Wang; Aimin Xu
Journal:  J Biol Chem       Date:  2010-08-16       Impact factor: 5.157

5.  FATP1 is an insulin-sensitive fatty acid transporter involved in diet-induced obesity.

Authors:  Qiwei Wu; Angelica M Ortegon; Bernice Tsang; Holger Doege; Kenneth R Feingold; Andreas Stahl
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

6.  Gain-of-function lipoprotein lipase variant rs13702 modulates lipid traits through disruption of a microRNA-410 seed site.

Authors:  Kris Richardson; Jennifer A Nettleton; Noemi Rotllan; Toshiko Tanaka; Caren E Smith; Chao-Qiang Lai; Laurence D Parnell; Yu-Chi Lee; Jari Lahti; Rozenn N Lemaitre; Ani Manichaikul; Margaux Keller; Vera Mikkilä; Julius Ngwa; Frank J A van Rooij; Christie M Ballentyne; Ingrid B Borecki; L Adrienne Cupples; Melissa Garcia; Albert Hofman; Luigi Ferrucci; Dariush Mozaffarian; Mia-Maria Perälä; Olli Raitakari; Russell P Tracy; Donna K Arnett; Stefania Bandinelli; Eric Boerwinkle; Johan G Eriksson; Oscar H Franco; Mika Kähönen; Michael Nalls; David S Siscovick; Denise K Houston; Bruce M Psaty; Jorma Viikari; Jacqueline C M Witteman; Mark O Goodarzi; Terho Lehtimäki; Yongmei Liu; M Carola Zillikens; Yii-Der I Chen; André G Uitterlinden; Jerome I Rotter; Carlos Fernandez-Hernando; Jose M Ordovas
Journal:  Am J Hum Genet       Date:  2012-12-13       Impact factor: 11.025

Review 7.  Therapeutic neuroprotective agents for amyotrophic lateral sclerosis.

Authors:  Rachna S Pandya; Haining Zhu; Wei Li; Robert Bowser; Robert M Friedlander; Xin Wang
Journal:  Cell Mol Life Sci       Date:  2013-07-18       Impact factor: 9.261

8.  Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis.

Authors:  Mahmoud Kiaei; Susanne Petri; Khatuna Kipiani; Gabrielle Gardian; Dong-Kug Choi; Junyu Chen; Noel Y Calingasan; Peter Schafer; George W Muller; Charles Stewart; Kenneth Hensley; M Flint Beal
Journal:  J Neurosci       Date:  2006-03-01       Impact factor: 6.167

9.  Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex.

Authors:  Atsuko Nakatsuka; Jun Wada; Izumi Iseda; Sanae Teshigawara; Kanji Higashio; Kazutoshi Murakami; Motoko Kanzaki; Kentaro Inoue; Takahiro Terami; Akihiro Katayama; Kazuyuki Hida; Jun Eguchi; Chikage Sato Horiguchi; Daisuke Ogawa; Yasushi Matsuki; Ryuji Hiramatsu; Hideo Yagita; Shigeru Kakuta; Yoichiro Iwakura; Hirofumi Makino
Journal:  Diabetes       Date:  2012-07-26       Impact factor: 9.461

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.